Overview

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of endocannabinoid system-targeting synthetic drug candidates. The Company’s lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Corbus licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 novel compounds targeting the endocannabinoid system from Jenrin Discovery LLC. The pipeline includes CRB-4001, a second generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist designed to eliminate blood-brain barrier penetration and subsequent brain CB1 receptor occupancy that mediates the neuropsychiatric adverse events associated with first-generation CB1 inverse agonists. Potential indications for CRB-4001 include nonalcoholic steatohepatitis, primary biliary cholangitis, idiopathic pulmonary fibrosis, radiation-induced pulmonary fibrosis, myocardial fibrosis after myocardial infarction and acute interstitial nephritis. Corbus plans to start a Phase 1 study of CRB-4001 in 2019, intended to be followed by a National Institutes of Health (NIH)-funded proof-of-concept Phase 2 study.

Management Team

Yuval Cohen, PhD
Chief Executive Officer, Director

Craig Millian, MBA
Chief Commercial Officer

Sean Moran, CPA, MBA
Chief Financial Officer

Barbara White, MD
Chief Medical Officer

Robert Discordia, Ph.D.
Vice President, Pharmaceutical Development & Manufacturing

Ross Lobell
Vice President, Regulatory Affairs

Contact Information

Corbus Pharmaceuticals Holdings, Inc.
500 River Ridge Drive
Norwood, MA 02062

Nasdaq: CRBP

<table>
<thead>
<tr>
<th>Share Price</th>
<th>$7.95</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>1.11m</td>
</tr>
<tr>
<td>Shares Outstanding</td>
<td>72,490,449</td>
</tr>
<tr>
<td>Market Cap</td>
<td>$576.3m</td>
</tr>
<tr>
<td>52 Week High</td>
<td>$8.78</td>
</tr>
<tr>
<td>52 Week Low</td>
<td>$3.29</td>
</tr>
</tbody>
</table>

as of 07/03/2020
Recent News

Monday, June 29, 2020 - 08:05 AM
Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress

Monday, June 22, 2020 - 08:05 AM
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis

Monday, June 01, 2020 - 08:05 AM
Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis

Wednesday, May 27, 2020 - 08:05 AM
Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

Friday, May 22, 2020 - 08:05 AM
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress

DISCLAIMER

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.